[New York] Advancing the Safe Use of Healthcare Products

Add this event to your calendar:
28/11/2017 16:30 28/11/2017 20:00 America/New_York [New York] Advancing the Safe Use of Healthcare Products New York Genome Center , 101 6th Ave, 1st floor , New York , NY 10013 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY

[New York] Advancing the Safe Use of Healthcare Products

New York Genome Center , 101 6th Ave, 1st floor , New York , NY 10013

November 28, 2017 from 16:30 PM to 20:00 PM (EST)

$10 - $35

On November 28, 2017, Johnson & Johnson will unveil and hear from the winner of the Advancing the Safe Use of Healthcare Products QuickFire Challenge.

This challenge is one in a series of QuickFire Challenges designed to draw the best thinking from experts on healthcare solutions for patients and consumers. We believe a good idea can come from anywhere, and by working together, we can spark the next great idea that will change the trajectory of health.

More than 95 submissions from physicians, researchers and others in industry and academia were considered in this challenge, which called for innovative ideas to help advance the safe use of healthcare products. We asked for ideas that will:

  • Empower patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).
  • Improve training and development for surgeons by identifying new models that simulate the operating room environment.
  • Empower patients and consumers to more safely administer and handle healthcare products.

In addition to hearing from the winner, two of Johnson & Johnson’s leaders, Joanne Waldstreicher, Chief Medical Officer and Melinda Richter, Head of JLABS, Johnson & Johnson Innovation, will be joined by Arthur Caplan, founding head of the Division of Bioethics at NYU Langone Medical Center, for a panel discussion around fostering innovation to enhance safety for those who use medical products every day.

Accelerating research, leading values-driven decision-making, creating a cutting-edge single medical safety standard, and encouraging innovation while striving to improve the lives of patients and consumers is what drives the Johnson & Johnson Office of the Chief Medical Officer and JLABS.

3:30 PM | Registration and Networking
4:00 PM | Opening & Intro of QFC Winner
4:15 PM | QFC Winner Presentation
4:25 PM | Award Presentation
4:30 PM | Panel
5:30 PM | Networking
7:00 PM | Program Close

Arthur Caplan | Drs. William F and Virginia Connolly Mitty Professor, Bioethics, Department of Population Health & Founding Head, Division of Medical Ethics at NYU School of Medicine read bio»
[moderator] Melinda Richter | Global Head of Johnson & Johnson Innovation, JLABS read bio»
Joanne Waldstreicher | Chief Medical Officer, Johnson & Johnson read bio»

FREE | General Public

New York Genome Center
101 6th Ave, 1st floor
New York, NY 10013

Speakers' Biographies:
Arthur Caplan | Drs. William F and Virginia Connolly Mitty Professor, Bioethics, Department of Population Health & Founding Head, Division of Medical Ethics at NYU School of Medicine
Arthur Leonard Caplan is currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.
Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.
Dr. Caplan is the author or editor of thirty-five books and over 725 papers in peer reviewed journals. His most recent books are The Ethics of Sport, (Oxford University Press, 2016 with Brendan Parent) and Vaccination Ethics and Policy , (MIT Press, 2017 with Jason Schwartz).
He is currently the ethics advisor to the U.S. Department of Defenses’s Defense Advanced Research Projects Agency on synthetic biology, a member of the University of Pennsylvania’s External Advisory Committee for its Orphan Disease Center, a member of the Ethics and Ebola Working Group of the World Health Organization and an advisor to the National Institutes of Health on organ transplantation. Dr. Caplan also serves as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.

Melinda Richter | Global Head of Johnson & Johnson Innovation, JLABS (JLABS)
As Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.
Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).

Joanne Waldstreicher | Chief Medical Officer, Johnson & Johnson
Joanne Waldstreicher, M.D., is Chief Medical Officer, Johnson & Johnson. In this role, she has oversight across pharmaceuticals, devices and consumer products for safety, epidemiology, clinical and regulatory operations transformation, internal and external partnerships and collaborations supporting development of the ethical science, technology and R&D policies, including those related to clinical trial transparency and compassionate access. Joanne also chairs the Pharmaceuticals (Janssen) R&D Development Committee and supports the Device and Consumer Development Committees, which review late stage development programs in the pipeline. She also holds an appointment as a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine.
Among her prior roles in Janssen, Joanne was responsible for late-stage development spanning the areas of neuroscience, cardiovascular and metabolism. She also led Endocrinology clinical research at Merck, overseeing programs in atherosclerosis, obesity, diabetes, urology and dermatology.
Joanne graduated Cum Laude from Harvard Medical School, completed her residency at Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital. She has received numerous awards and scholarships, and authored numerous papers. In 2016, the National Association of Female Executives named her Healthcare Champion of the Year.
Joanne combines broad experience in science and medicine with a passion for advancing transparency and ethics, with a goal of improving the lives of patients and consumers worldwide.

Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact

Related content